Trichoscopy in Diagnosis of Immunobollous Diseases

July 26, 2018 updated by: tasbeeh salah

The Role of Trichoscopy in the Preliminary Diagnosis of Immunobollous Diseases

Autoimmune bullous diseases are a variety of skin diseases that are characterized by the presence of bullae or blisters. Most of these diseases are associated with substantial morbidity and mortality. They are classified according to the site of blister formation into intraepidermal as pemphigus valgaris and foliaceus, and subepidermal as bullous pemphigoid and dermatitis herpetiformis. These lesions commonly affect the scalp and manifest as blisters, erosions and crustations.

Trichoscopy (hair and scalp dermoscopy) is a non-invasive technique in which either a handheld dermoscope or a digital videodermoscope can be used to visualize hair and scalp structures. The method has well-established position as an ancillary tool in the diagnosis of many disorders such as, tinea capitis, alopecia areata, androgenetic alopecia, discoid lupus erythematosus, lichen planopilaris, folliculitis decalvans and other hair and scalp diseases. Few studies have reported that immunobullous diseases present characteristic trichoscopic patterns. So, Trichoscopy can be used as a rapid in-office preliminary diagnostic tool in the differential diagnosis of these diseases.

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

Autoimmune bullous diseases are a variety of skin diseases that are characterized by the presence of bullae or blisters. Most of these diseases are associated with substantial morbidity and mortality. They are classified according to the site of blister formation into intraepidermal as pemphigus valgaris and foliaceus, and subepidermal as bullous pemphigoid and dermatitis herpetiformis. These lesions commonly affect the scalp and manifest as blisters, erosions and crustations.

Pemphigus is a group of potentially life-threatening intraepidermal vesiculobullous autoimmune diseases that affect the skin and mucous membranes. It is characterized by the presence of circulating and tissue-bound autoantibodies directed against desmogleins, which attaches adjacent epidermal cells via desmosomes. When autoantibodies attack desmogleins, the cells become separated from each other and the epidermis becomes "unglued", a phenomenon called acantholysis. This causes blisters that slough off and turn into sores.

In pemphigus vulgaris (PV) blisters and erosions occurs in the skin and/or mucous membranes, and circulating autoantibodies are directed against desmoglein 3 and 1. In pemphigus foliaceus, there is mainly skin involvement and antibodies are exclusively directed against desmoglein 1. Histologically, both subtypes exhibit intraepidermal blister formation with loss of keratinocytes' adhesion. However, in Pemphigus vulgaris, the split occurs just above the basal cell layer, whereas in pemphigus foliaceus it occurs in the upper part of the epidermis, at the level of the granular layer.

Bullous pemphigoid (BP) is a chronic, autoimmune, subepidermal, blistering skin disease that rarely involves mucous membranes. It is characterized by the presence of immunoglobulin G (IgG) autoantibodies specific for the hemidesmosomal BP antigens BP230 (BPAg1) and BP180 (BPAg2). The lesions of BP may initially start as an urticarial eruption, which over a course of weeks to months, develops into bullae. The lesions are usually prurutic. Once formed, blisters are large and tense, with a round or oval shape. Discrete lesions arise on normal or erythematous skin and are scattered throughout the body.

Dermatitis herpetiformis (DH) is an autoimmune blistering disorder associated in most patients with a gluten-sensitive enteropathy (GSE). DH is characterized by pruritic erythematous clusters of multiforme lesions, frequently in herpetiform pattern. Histopathologically, there are neutrophilic micro-abscesses in dermal papillae, dermal infiltration of neutrophils and eosinophils, and the formation of subepidermal vesicles. Blisters form within the lamina lucida.

Diagnosis of these diseases is based on clinical, histopathological, immunofluorescence and immunoserological tests. Because of the limited resources in our institution, diagnosis relies mainly on clinical and histopathological evaluations.

Trichoscopy (hair and scalp dermoscopy) is a non-invasive technique in which either a handheld dermoscope or a digital videodermoscope can be used to visualize hair and scalp structures. The method has well-established position as an ancillary tool in the diagnosis of many disorders such as, tinea capitis, alopecia areata, androgenetic alopecia, discoid lupus erythematosus, lichen planopilaris, folliculitis decalvans and other hair and scalp diseases. Few studies have reported that immunobullous diseases present characteristic trichoscopic patterns. So, Trichoscopy can be used as a rapid in-office preliminary diagnostic tool in the differential diagnosis of these diseases.

Study Type

Observational

Enrollment (Anticipated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

upper Egyptian patients

Description

Inclusion Criteria:

  • Patients with clinical & histopathological diagnosis of autoimmune bullous diseases.

Exclusion Criteria:

  • Patients who will not consent.
  • Patients with any concomitant dermatological diseases.
  • Pregnancy and lactation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
trichoscopic features of autoimmune bullous diseases and frequency of each feature.
Time Frame: 1year
Detect trichoscopic features of autoimmune bullous diseases and frequency of each feature.
1year
diagnostic accuracy of trichoscopy in autoimmune bullous diseases.
Time Frame: 1year
detect diagnostic accuracy of trichoscopy in autoimmune bullous diseases..
1year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Nagwa Easa, prof, Prof

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

December 1, 2018

Primary Completion (Anticipated)

December 1, 2019

Study Completion (Anticipated)

June 1, 2020

Study Registration Dates

First Submitted

March 15, 2018

First Submitted That Met QC Criteria

March 20, 2018

First Posted (Actual)

March 27, 2018

Study Record Updates

Last Update Posted (Actual)

July 30, 2018

Last Update Submitted That Met QC Criteria

July 26, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • AUEC

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on IMMUNOBULLOUS DISEASES

Clinical Trials on trichoscopy

Subscribe